Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuromed Deal With Alza Will Accelerate Commercialization Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Neuromed will develop a sales force to launch OROS hydromorphone in the U.S. in 2009 under a collaboration with the J&J subsidiary.

You may also be interested in...



Merck, Neuromed Discontinue N-Type Calcium Channel Blocker For Pain

Companies will continue a joint research effort to deliver a “best in class” candidate, Neuromed CEO Gallen tells “The Pink Sheet” DAILY.

Merck, Neuromed Discontinue N-Type Calcium Channel Blocker For Pain

Companies will continue a joint research effort to deliver a “best in class” candidate, Neuromed CEO Gallen tells “The Pink Sheet” DAILY.

Merck Signs On For Neuromed’s Chronic Pain Agent

Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel